Two Sigma Investments
PRME icon

Two Sigma Investments’s Prime Medicine PRME Stock Holding History

Two Sigma Investments’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.47M Sell
1,572,811
-56,513
-3% -$215K ﹤0.01% 1902
2025
Q4 		$5.65M Buy
1,629,324
+1,181,657
+264% +$5.26M 0.01% 1600
2025
Q3 		$2.48M Buy
447,667
+189,244
+73% +$769K ﹤0.01% 1987
2025
Q2 		$638K Sell
258,423
-347
-0.1% -$535 ﹤0.01% 2475
2025
Q1 		$515K Buy
258,770
+92,571
+56% +$236K ﹤0.01% 2510
2024
Q4 		$485K Sell
166,199
-152,374
-48% -$535K ﹤0.01% 2552
2024
Q3 		$1.23M Sell
318,573
-362,903
-53% -$1.68M ﹤0.01% 1997
2024
Q2 		$3.5M Buy
681,476
+173,398
+34% +$1.05M 0.01% 1183
2024
Q1 		$3.56M Buy
508,078
+239,716
+89% +$1.82M 0.01% 1154
2023
Q4 		$2.38M Buy
268,362
+175,369
+189% +$1.35M 0.01% 1399
2023
Q3 		$887K Buy
+92,993
New +$1.21M ﹤0.01% 2005

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Two Sigma Investments's PRME Position: Q1 2026 in Review

Two Sigma Investments reduced its Prime Medicine (PRME) stake by 3.5% in Q1 2026, selling an estimated $215K and leaving 1,572,811 shares worth $5.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Two Sigma Investments first reported a position in PRME in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.65M in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Two Sigma Investments held 1,572,811 shares of Prime Medicine worth $5.47M as of Q1 2026.
  • Two Sigma Investments sold 56,513 Prime Medicine shares in Q1 2026, an estimated $215K.
  • Prime Medicine made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #1902 holding.
  • Two Sigma Investments first reported a position in Prime Medicine in Q3 2023 and has held it in 11 quarters since.
  • Two Sigma Investments's Prime Medicine position peaked at $5.65M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.